No Data
No Data
Express News | Coherus BioSciences Appoints Rita Karachun, Cpa, Cgma to Its Board of Directors
Coherus Management to Present at the 2024 Jefferies Global Healthcare Conference
H.C. Wainwright Maintains Coherus BioSciences(CHRS.US) With Buy Rating, Maintains Target Price $12
H.C. Wainwright analyst Douglas Tsao maintains $Coherus BioSciences(CHRS.US)$ with a buy rating, and maintains the target price at $12.According to TipRanks data, the analyst has a success rate of 37.
Express News | HC Wainwright & Co. Reiterates Buy on Coherus BioSciences, Maintains $12 Price Target
Buy Rating Affirmed for Coherus Biosciences on CHS-114's Promising Clinical Data and Strong Financial Projections
Express News | Coherus BioSciences: Chs-114 Shown to Have Acceptable Safety Profile With No Dose-Limiting Toxicities in Heavily Pretreated Patients With Solid Tumors
No Data
买跌不追涨 : This news feels average
TrytosaveabitOP 买跌不追涨: As far as compared to other BIO news! You are correct